226 related articles for article (PubMed ID: 25980552)
41. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder.
Raskin J; Xu JY; Kajdasz DK
Int Psychogeriatr; 2008 Apr; 20(2):309-27. PubMed ID: 17588276
[TBL] [Abstract][Full Text] [Related]
42. Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder.
Soares CN; Endicott J; Boucher M; Fayyad RS; Guico-Pabia CJ
CNS Spectr; 2014 Dec; 19(6):519-27. PubMed ID: 24571916
[TBL] [Abstract][Full Text] [Related]
43. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
[TBL] [Abstract][Full Text] [Related]
44. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
Sheehan DV; Harnett-Sheehan K; Spann ME; Thompson HF; Prakash A
Int Clin Psychopharmacol; 2011 Mar; 26(2):75-83. PubMed ID: 21102344
[TBL] [Abstract][Full Text] [Related]
45. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
[TBL] [Abstract][Full Text] [Related]
46. Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial.
Arnold LM; Wang F; Ahl J; Gaynor PJ; Wohlreich MM
Arthritis Res Ther; 2011 Jun; 13(3):R86. PubMed ID: 21668963
[TBL] [Abstract][Full Text] [Related]
47. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
48. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder.
Strawn JR; Prakash A; Zhang Q; Pangallo BA; Stroud CE; Cai N; Findling RL
J Am Acad Child Adolesc Psychiatry; 2015 Apr; 54(4):283-93. PubMed ID: 25791145
[TBL] [Abstract][Full Text] [Related]
49. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
50. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.
Lam RW; Wajsbrot DB; Meier E; Pappadopulos E; Mackell JA; Boucher M
J Psychopharmacol; 2017 Sep; 31(9):1204-1214. PubMed ID: 28718346
[TBL] [Abstract][Full Text] [Related]
51. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Emslie GJ; Wells TG; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
J Child Adolesc Psychopharmacol; 2015 May; 25(4):293-305. PubMed ID: 25978741
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
Papakostas GI; Culpepper L; Fayyad RS; Musgnung J; Guico-Pabia CJ
Int Clin Psychopharmacol; 2013 Nov; 28(6):312-21. PubMed ID: 23881185
[TBL] [Abstract][Full Text] [Related]
53. Implications of pain in generalized anxiety disorder: efficacy of duloxetine.
Hartford JT; Endicott J; Kornstein SG; Allgulander C; Wohlreich MM; Russell JM; Perahia DG; Erickson JS
Prim Care Companion J Clin Psychiatry; 2008; 10(3):197-204. PubMed ID: 18615176
[TBL] [Abstract][Full Text] [Related]
54. The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study.
Wang Y; Bernanke J; Peterson BS; McGrath P; Stewart J; Chen Y; Lee S; Wall M; Bastidas V; Hong S; Rutherford BR; Hellerstein DJ; Posner J
Lancet Psychiatry; 2019 Aug; 6(8):667-674. PubMed ID: 31248841
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
57. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ
J Clin Psychopharmacol; 2011 Oct; 31(5):569-76. PubMed ID: 21869698
[TBL] [Abstract][Full Text] [Related]
58. Validation of the geriatric anxiety inventory in a duloxetine clinical trial for elderly adults with generalized anxiety disorder.
Ball SG; Lipsius S; Escobar R
Int Psychogeriatr; 2015 Sep; 27(9):1533-9. PubMed ID: 25925598
[TBL] [Abstract][Full Text] [Related]
59. Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation.
Rovera C; Mauri MC; Bertin E; Di Pace C; Paletta S; Reggiori A; De Gaspari IF; Cattaneo D; Mari D; Altamura AC
Hum Psychopharmacol; 2016 Sep; 31(5):349-55. PubMed ID: 27400882
[TBL] [Abstract][Full Text] [Related]
60. Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study.
Bilodeau M; Simon T; Beauchamp MH; Lespérance P; Dubreucq S; Dorée JP; Tourjman SV
J Atten Disord; 2014 Feb; 18(2):169-75. PubMed ID: 22582349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
